Product Name :
MYCi975
Description:
MYCi975 (NUCC-0200975) is an orally active MYC inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression. MYCi975 (NUCC-0200975) exhibits potent anti-tumor efficacy with good tolerability, increases tumor immune cell infiltration, and sensitizes tumors to anti-PD1 immunotherapy.
CAS:
2289691-01-4
Molecular Weight:
561.30
Formula:
C25H16Cl2F6N2O2
Chemical Name:
4′-chloro-6-[(4-chlorophenyl)methoxy]-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-ol
Smiles :
CN1N=C(C=C1C1C=CC(OCC2C=CC(Cl)=CC=2)=C(C=1O)C1C=C(C(Cl)=CC=1)C(F)(F)F)C(F)(F)F
InChiKey:
VSDFDVBYONIJLD-UHFFFAOYSA-N
InChi :
InChI=1S/C25H16Cl2F6N2O2/c1-35-19(11-21(34-35)25(31,32)33)16-7-9-20(37-12-13-2-5-15(26)6-3-13)22(23(16)36)14-4-8-18(27)17(10-14)24(28,29)30/h2-11,36H,12H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
MYCi975 (NUCC-0200975) is an orally active MYC inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression. MYCi975 (NUCC-0200975) exhibits potent anti-tumor efficacy with good tolerability, increases tumor immune cell infiltration, and sensitizes tumors to anti-PD1 immunotherapy.|Product information|CAS Number: 2289691-01-4|Molecular Weight: 561.30|Formula: C25H16Cl2F6N2O2|Chemical Name: 4′-chloro-6-[(4-chlorophenyl)methoxy]-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-ol|Smiles: CN1N=C(C=C1C1C=CC(OCC2C=CC(Cl)=CC=2)=C(C=1O)C1C=C(C(Cl)=CC=1)C(F)(F)F)C(F)(F)F|InChiKey: VSDFDVBYONIJLD-UHFFFAOYSA-N|InChi: InChI=1S/C25H16Cl2F6N2O2/c1-35-19(11-21(34-35)25(31,32)33)16-7-9-20(37-12-13-2-5-15(26)6-3-13)22(23(16)36)14-4-8-18(27)17(10-14)24(28,29)30/h2-11,36H,12H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 250 mg/mL (445.{{Tildrakizumab} medchemexpress|{Tildrakizumab} Interleukin Related|{Tildrakizumab} Biological Activity|{Tildrakizumab} In Vivo|{Tildrakizumab} supplier|{Tildrakizumab} Epigenetics} 39 mM).{{Pretomanid} web|{Pretomanid} Antibiotic|{Pretomanid} Purity & Documentation|{Pretomanid} Formula|{Pretomanid} supplier|{Pretomanid} Epigenetics} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24458656 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MYCi975 (3 days) inhibits P493-6, MV411, and SK-N-B2 cells viability in an MYC-dependent manner with IC50s of 3.7, 3.9, 6.4 μM, respectively.|In Vivo:|MYCi975 exhibits excellent pharmacokinetic profiles following p.o., i.p., or i.v. administration. The half-lives observed are 7 and 12 hours when dosed at 100 and 250 mg/kg p.o., respectively. The Cmax values attained are 41,533 ng/mL (74 μM) and 54,000 ng/mL (96 μM), respectively. MYCi975 significantly inhibits tumor growth and increases survival in the MycCaP allograft model with animals tolerating a 100 mg/kg/day i.p. dosing for 14 days.|Products are for research use only. Not for human use.|